The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The recent FDA approval of IsaVRd for transplant-ineligible newly diagnosed myeloma
In this video, Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, briefly comments on the recent Food and Drug Administration (FDA) approval of isatuximab combined with standard-of-care bortezomib, lenalidomide, and dexamethasone (Isa-VRd). This regimen is now approved for the treatment of newly diagnosed transplant-ineligible patients with multiple myeloma (MM). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, you know, as every new drug approved for multiple myeloma is good news for patients. We already have anti-CD38 antibody daratumumab for several years now. Having another therapy, of course, creates an advantage and more opportunities. Of course, it will be important to understand in which patients we should do both, one or the other. And in particular, one of our investigations is trying to understand if patients relapsing after one antibody should be treated with the other one because the binding sites are different and some data will be presented at ASH this year about that...
Well, you know, as every new drug approved for multiple myeloma is good news for patients. We already have anti-CD38 antibody daratumumab for several years now. Having another therapy, of course, creates an advantage and more opportunities. Of course, it will be important to understand in which patients we should do both, one or the other. And in particular, one of our investigations is trying to understand if patients relapsing after one antibody should be treated with the other one because the binding sites are different and some data will be presented at ASH this year about that.
Read more...
